Meeder Asset Management Inc Allakos Inc. Transaction History

Meeder Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$8.55 - $111.89 $4,950 - $64,784	-579 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$76.53 - $110.43 $28,316 - $40,859	370 Added 177.03%	579 $60,000
Q2 2021 Aug 09, 2021	BUY	$85.37 - $114.1 $17,842 - $23,846	209 New	209 $18,000
Q4 2020 Feb 09, 2021	SELL	$79.58 - $152.45 $59,525 - $114,032	-748 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$66.43 - $90.99 $49,689 - $68,060	748 New	748 $60,000
Q1 2020 May 15, 2020	SELL	$44.49 - $93.39 $1,913 - $4,015	-43 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$66.49 - $137.73 $864 - $1,790	-13 Reduced 23.21%	43 $4,000
Q3 2019 Oct 17, 2019	BUY	$31.0 - $89.73 $1,736 - $5,024	56 New	56 $4,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $91.5M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.